Promomed has registered a drug for reducing excess weight and treating obesity, Tirzetta. It is the first Russian competitor of the well-known and not available in Russia drug Mounjaro. According to Strategy Partners' research, the Russian market for drugs to combat overweight and diabetes will grow by almost 80% to reach ₽17 billion in 2025.
Warning BlackTerminal uses cookies in order to personalize and improve the usability of the service. If you do not want to use cookies, please change your browser settings. Accept